Lei Yu1, Michael W Lutz2, Jose M Farfel3, Robert S Wilson4, Daniel K Burns5, Ann M Saunders5, Philip L De Jager6, Lisa L Barnes4, Julie A Schneider7, David A Bennett7. 1. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA. Electronic address: lei_yu@rush.edu. 2. Department of Neurology, Duke University School of Medicine, Durham, NC, USA. 3. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Discipline of Geriatrics, Faculty of Medicine of the University of Sao Paulo, Brazil. 4. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA; Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA. 5. Zinfandel Pharmaceuticals, Inc., Research Triangle Park, NC, USA. 6. Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY, USA; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA. 7. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Abstract
INTRODUCTION: The study investigated the role of neuropathologies in the relationship between TOMM40 '523 genotype and late-life cognitive decline. METHODS: Participants were community-dwelling older persons who had annual cognitive assessments and brain autopsies after death. Genotyping used DNA from peripheral blood or postmortem brain tissue. Linear mixed models assessed the extent to which the association of '523 genotype with cognitive decline is attributable to neuropathologies. RESULTS: Relative to ε3/ε3 homozygotes with '523-S/VL or '523-VL/VL genotype, both '523-L carriers and ε3/ε3 homozygotes with '523-S/S genotype had faster cognitive decline. The association of '523-L with cognitive decline was attenuated and no longer significant after controlling for Alzheimer's and other neuropathologies. By contrast, the association of '523-S/S was unchanged. DISCUSSION: There are two distinct TOMM40 '523 signals in relation to late-life cognitive decline. One signal primarily acts through AD and other common neuropathologies, whereas the other operates through a different mechanism.
INTRODUCTION: The study investigated the role of neuropathologies in the relationship between TOMM40 '523 genotype and late-life cognitive decline. METHODS:Participants were community-dwelling older persons who had annual cognitive assessments and brain autopsies after death. Genotyping used DNA from peripheral blood or postmortem brain tissue. Linear mixed models assessed the extent to which the association of '523 genotype with cognitive decline is attributable to neuropathologies. RESULTS: Relative to ε3/ε3 homozygotes with '523-S/VL or '523-VL/VL genotype, both '523-L carriers and ε3/ε3 homozygotes with '523-S/S genotype had faster cognitive decline. The association of '523-L with cognitive decline was attenuated and no longer significant after controlling for Alzheimer's and other neuropathologies. By contrast, the association of '523-S/S was unchanged. DISCUSSION: There are two distinct TOMM40 '523 signals in relation to late-life cognitive decline. One signal primarily acts through AD and other common neuropathologies, whereas the other operates through a different mechanism.
Authors: A Payton; P Sindrewicz; V Pessoa; H Platt; M Horan; W Ollier; V J Bubb; N Pendleton; J P Quinn Journal: Neurobiol Aging Date: 2015-12-08 Impact factor: 4.673
Authors: Robert M Koffie; Tadafumi Hashimoto; Hwan-Ching Tai; Kevin R Kay; Alberto Serrano-Pozo; Daniel Joyner; Steven Hou; Katherine J Kopeikina; Matthew P Frosch; Virginia M Lee; David M Holtzman; Bradley T Hyman; Tara L Spires-Jones Journal: Brain Date: 2012-05-26 Impact factor: 13.501
Authors: Sukriti Nag; Lei Yu; Ana W Capuano; Robert S Wilson; Sue E Leurgans; David A Bennett; Julie A Schneider Journal: Ann Neurol Date: 2015-04-22 Impact factor: 10.422
Authors: D A Bennett; R S Wilson; J A Schneider; D A Evans; N T Aggarwal; S E Arnold; E J Cochran; E Berry-Kravis; J L Bienias Journal: Neurology Date: 2003-01-28 Impact factor: 9.910
Authors: Richard J Caselli; Amylou C Dueck; Matthew J Huentelman; Michael W Lutz; Ann M Saunders; Eric M Reiman; Allen D Roses Journal: Alzheimers Dement Date: 2012-11 Impact factor: 21.566
Authors: Lei Yu; Patricia A Boyle; Sukriti Nag; Sue Leurgans; Aron S Buchman; Robert S Wilson; Zoe Arvanitakis; Jose M Farfel; Philip L De Jager; David A Bennett; Julie A Schneider Journal: Neurobiol Aging Date: 2015-08-15 Impact factor: 4.673
Authors: Andrea R Zammit; Graciela Muniz-Terrera; Mindy J Katz; Charles B Hall; Ali Ezzati; David A Bennett; Richard B Lipton Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Patricia A Boyle; Lei Yu; Robert S Wilson; Sue E Leurgans; Julie A Schneider; David A Bennett Journal: Ann Neurol Date: 2018-01-14 Impact factor: 10.422
Authors: David A Bennett; Aron S Buchman; Patricia A Boyle; Lisa L Barnes; Robert S Wilson; Julie A Schneider Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Megan C Bakeberg; Anastazja M Gorecki; Abigail L Pfaff; Madison E Hoes; Sulev Kõks; P Anthony Akkari; Frank L Mastaglia; Ryan S Anderton Journal: NPJ Parkinsons Dis Date: 2021-07-07